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ABSTRACT
Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to 
multiple benign tumors of the central and peripheral nervous systems, including vestibular 
schwannomas. Currently, there are no FDA approved drug therapies for NF2. Loss of 
function of merlin encoded by the NF2 tumor suppressor gene leads to activation of multiple 
mitogenic signaling cascades, including platelet-derived growth factor receptor (PDGFR) 
and SRC in Schwann cells. The goal of this study was to determine whether ponatinib, an 
FDA-approved ABL/SRC inhibitor, reduced proliferation and/or survival of merlin-deficient 
human Schwann cells (HSC). Merlin-deficient HSC had higher levels of phosphorylated 
PDGFRα/β, and SRC than merlin-expressing HSC. A similar phosphorylation pattern was 
observed in phospho-protein arrays of human vestibular schwannoma samples compared 
to normal HSC. Ponatinib reduced merlin-deficient HSC viability in a dose-dependent 
manner by decreasing phosphorylation of PDGFRα/β, AKT, p70S6K, MEK1/2, ERK1/2 
and STAT3. These changes were associated with decreased cyclin D1 and increased 
p27Kip1levels, leading to a G1 cell-cycle arrest as assessed by Western blotting and flow 
cytometry. Ponatinib did not modulate ABL, SRC, focal adhesion kinase (FAK), or paxillin 
phosphorylation levels. These results suggest that ponatinib is a potential therapeutic 
agent for NF2-associated schwannomas and warrants further in vivo investigation.
INTRODUCTION
Neurofibromatosis type 2 (NF2) is a non-malignant 
tumor disorder affecting the peripheral and central nervous 
systems. Although bilateral vestibular schwannomas (VS) 
are a diagnostic hallmark of the disorder, NF2 patients 
typically develop multiple meningiomas, ependymomas 
and other schwannomas as well. VS lead to deafness, 
tinnitus, imbalance and can cause life-threatening 
brainstem compression [1]. NF2 is caused by mutations 
in the NF2 gene that encodes the tumor suppressor protein 
known as merlin or schwannomin [2, 3]. Merlin belongs 
to the Band 4.1 family of proteins that link the actin 
cytoskeleton to membrane receptors and transporters. 
Merlin modulates the activity of multiple signaling 
pathways that control cell size, morphology, cell adhesion, 
proliferation, and survival. These include receptor tyrosine 
kinase (RTK; e.g. ErbB2/3, PDGFR, EGFR, HGFR), small 
GTPases, FAK/SRC, the mammalian target of rapamycin 
(mTOR)/PI3K/AKT, and Hippo pathways [4]. Currently, 
surgery and radiation are the mainstream treatment options 
for NF2-associated tumors. Depending on the tumor 
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size and location, there are significant adverse effects 
associated with their removal. While an understanding 
of the biological functions of merlin is progressing, well-
defined druggable molecular targets have yet to emerge. 
Increasingly, patients are treated off-label with the anti-
angiogenic agent bevacizumab that also reduces edema in 
schwannomas without affecting the tumor cells. Dosing 
regimens are being optimized to reduce associated kidney 
toxicity observed with prolonged bevacizumab treatment 
[1, 5]. However, to date there are no FDA-approved 
therapies that target schwannoma cells directly and reduce 
morbidity and mortality of NF2 patients [1, 6].
Because of the slow-growing and benign nature 
of NF2 schwannomas, conventional chemotherapeutic 
agents are unsuccessful. Several RTK inhibitors have been 
investigated in preclinical studies and clinical trials with 
limited patient response. These include lapatinib (an EGFR/
ErbB2 inhibitor; NCT00973739, NCT00863122), nilotinib 
(a PDGFR and c-kit inhibitor; NCT01201538), sorafenib 
(a VEGFR-2, PDFGRβ, and c-kit inhibitor), and axitinib 
(a VEGFR, c-kit, and PDGFRβ inhibitor; NCT02129647) 
[1, 7]. We selected ponatinib for evaluation because it is 
an FDA-approved drug that inhibits a relevant RTK, the 
PDGFR, and a downstream effector common to several 
NF2 activated pathways, the non-receptor tyrosine kinase 
SRC. PDGFR and SRC signaling regulate cell survival, 
proliferation, migration and angiogenesis in many cell types 
[8, 9]. PDGFR is over-expressed and activated in VS and 
primary human schwannoma cells, consistent with merlin’s 
role in downregulating surface levels of growth factor 
receptors [10-13]. In HEI-193 schwannoma cells, merlin 
overexpression inhibits cell proliferation by promoting 
PDGFR internalization and degradation [14]. There is 
evidence that SRC activity is deregulated in cells with loss 
of merlin function and thus is a candidate for therapeutic 
targeting. In human schwannoma cells, SRC activity is 
increased compared to normal Schwann cells, and in mouse 
glia cells, merlin inhibits proliferation by modulating SRC 
activity [15, 16]. Lastly, primary human schwannoma cells 
treated with the SRC inhibitor SU6656 exhibit decreased 
transcription of proliferation-associated genes [17]. Thus, 
an inhibitor that targets both PDGFR and SRC might have 
therapeutic value for NF2-associated tumors.
Ponatinib (AP24534, brand name: Iclusig®) is a 
third generation type IIA inhibitor of ABL/SRC tyrosine 
kinase (TK). It is orally active and initially received 
accelerated approval in 2012 for adult patients with 
chronic myeloid leukemia (CML) and Philadelphia 
chromosome-positive acute lymphoblastic leukemia 
(Ph+ ALL) that are T315I-positive and are not candidates 
for other TK inhibitors. Ponatinib binds the inactive, 
DFG-out (aspartic acid, phenylalanine and glycine) 
ABL/SRC conformation [18, 19]. In a cell-free kinase 
screen, ponatinib inhibited SRC with IC
50
 of 5.4nM and 
PDGFRα and PDGFRβ with IC
50
 of 1.1nM and 7.7nM, 
respectively [19].
In this study, we measured the ability of ponatinib 
to decrease proliferation and survival of merlin-deficient 
HSC and vestibular schwannoma cells with NF2 mutations. 
We found that ponatinib caused a G
1
 cell-cycle arrest and 
mapped the regulatory signaling cascades modulated by the 
inhibitor. Our findings support further in vivo evaluation of 
ponatinib as a candidate drug for NF2 schwannomas.
RESULTS
Ponatinib decreases viability of merlin-deficient 
HSC and vestibular schwannoma (VS) cells
To create a suitable cell line for drug discovery 
studies, we first authenticated primary HSC based on their 
expression of human nuclear antigen and Schwann cell 
markers, S100, PLP, and O4 (Figure 1A). We then used 
lentiviral delivery of NF2-shRNA to reduce expression 
of merlin in the primary HSC. Merlin levels were stably 
reduced to nearly undetectable levels in the transduced 
cells compared to the parental HSC (Figure 1B, C). The 
merlin-deficient HSC did not contact inhibit but did not 
form aggregates and grows in multiple layers; many of 
these merlin-deficient HSC maintained an elongated 
morphology when cultured in the presence of serum and 
mitogens (Supplementary Figure 1AB). We measured 
basal levels of PDGFRα/β and SRC phosphorylation 
in primary HSC prior to and following knockdown of 
merlin. We found that depletion of merlin expression 
was associated with increased levels of p-PDGFRα/β and 
p-SRC compared to the parental HSC (Figure 1B). This 
finding agrees with previous reports of increased activation 
of the PDGFR and SRC pathways in human schwannomas 
compared to normal human nerve [10, 20, 21].
We screened the ability of ponatinib to reduce 
viability of multiple control and merlin-deficient HSC 
lines. As controls, we tested the parental wild-type HSC 
(HSC-WT), HSC expressing a scrambled shRNA construct 
(HSC-SCR), HSC expressing a Turbo-GFP shRNA 
(HSC-GFP), and merlin-deficient HSC lines (MD-HSC) 
expressing shRNA sequences that target the human NF2 
gene, (MD-HSC #45, #74 #75 and #77). All control HSC 
expressed merlin, whereas the HSCs transduced with 
shRNA constructs targeting the NF2 gene had nearly 
undetectable merlin levels (Figure 1D). We performed 48 
hour dose-response viability assays on the seven HSC lines 
in complete growth medium containing serum and growth 
factors. The results indicated that ponatinib reduced viability 
of all of the cell lines in a dose-dependent manner (Figure 
1E). Under the conditions tested, ponatinib was not selective 
for MD-HSC over scrambled, GFP or untransduced HSC 
(IC
50
 HSC-SCR= 3.3μM, HSC-GFP=2.4 μM, HSC-WT= 
2.3 μM, MD-HSC#45= 2.2 μM, MD-HSC#74= 3.3 μM, 
MD-HSC#75= 1.9 μM and MD-HSC#77=3.7 μM). The 
average maximal response at 10μM was a 71% decrease in 
cell viability. However, when control merlin-expressing cell 
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Figure 1: Ponatinib decreases HSC viability. (A) Characterization of primary HSC. Confocal Images of HSC expressing human and 
SC linage markers: human nuclear antigen (HNA, red), S100 (green), GAP43 (red), proteolipid protein (PLP, green), negative nestin (red), 
DAPI stained nuclei (blue) and F-actin was visualized with phaloidin-Alexa633 (white). Scale bar: 50μm. (B) Representative Western blots 
of primary HSC and merlin-deficient HSC (MD-HSC) lysates, merlin silencing increased levels of phosphorylated SRC and PDGFRα/β. 
(C) Western blotting for merlin and β-actin in control HSC and merlin deficient cells at increasing cell passages. (D) Western blot for 
merlin and β-actin in three control HSC lines and four merlin-deficient (knock-down) HSC lines. (E) Ponatinib dose-response CellTiter-
Fluor viability assay. Control HSC lines: SCR-HSC, GFP-HSC and WT-HSC and merlin-deficient HSC: #45, 74, 75, 77 were treated with 
increasing concentrations of ponatinib in constant 0.1% DMSO or vehicle alone for 48h. Viability is presented as a % of the DMSO control. 
Graph represents the mean ± SEM of three independent experiments. (F-G) WT-HSC and MD-HSC (#45) were maintained in serum free 
medium for 5-10 days and then treated with 0.25μM ponatinib for one week. Relative cell numbers was assessed using a crystal violet 
assay: (F) Representative 20X phase contrast images of cells. Scale bar= 100μm. (G) Cell viability calculated as a % of their respective 
DMSO control. Graph represent mean ± SEM of three independent experiments (** p<0.01, unpaired t-test, two tailed). (H) Viability of 
primary human VS cells treated for 48h with increasing ponatinib concentrations. Relative cell viability was assessed using a crystal violet 
assay and presented as % viability normalized to DMSO group. Plot of mean ± SEM of 6 replicates. VS1 (heterozygous deletion of 23 
nucleotides in exon 8 of the NF2 gene, non-irradiated, passage 2); VS2 (heterozygous missense c.1460T>A and p. I487N in exon 14 of the 
NF2 gene, non-irradiated, passage 2).
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line (HSC-WT) and merlin-deficient HSC (MD-HSC#45) 
were cultured in the absence of serum and mitogens, merlin-
deficient HSC were significantly more sensitive to 0.25 μM 
ponatinib than the merlin-expressing HSC (Figure 1F,G).
We tested ponatinib’s effect on cultured human 
vestibular schwannoma cells with NF2 mutations. We 
assessed relative cell viability using a crystal violet assay 
following 48 hour incubation with ponatinib. Cell viability 
was reduced by approximately 40% at 2μM in VS1 and 
VS2 compared to DMSO-treated cells in agreement with 
the IC
50
 obtained with our MD-HSC lines. (Figure 1H).
Ponatinib decreases viability of merlin-deficient 
HSC independent of the SRC/FAK/paxillin 
pathway
Ponatinib did not reduce net levels of ABL phos-
phorylation in merlin-deficient HSC (Figure 2A). Ponatinib 
induced a dose-dependent increase in the total SRC protein 
level but did not alter the levels of the other SRC family 
members, FYN and YES, that play important roles in SC 
biology as well (Figure 2B) [22, 23]. We found a slight 
increase in SRC-Tyr416 phosphorylation in merlin-deficient 
HSC treated with 0.3 to 3μM (with a peak at 1μM). The 
phosphorylation pattern, however, did not coincide with the 
increase in the SRC protein levels (Figure 2B).
Key effectors transducing extracellular matrix 
adhesion and growth factor-dependent stimuli in 
Schwann cells are the SRC substrates, FAK and paxillin, 
a focal adhesion-associated adaptor [24]. FAK is a 
key mediator of extracellular matrix-integrin and RTK 
signaling that is upregulated in schwannomas [10]. Upon 
FAK autophosphorylation at Tyr397, SRC binds the 
phosphorylated residue and phosphorylates FAK on Tyr576 
and Tyr577, resulting in stabilizing the activation loop of 
FAK in the active conformation and its binding to substrates, 
Figure 2: Ponatinib decreased merlin-deficient HSC viability independent of ABL/SRC/FAK pathway inhibition. 
Representative ponatinib dose-response Western blots (n=3). MD- HSC#45 plated in 12-well plates were treated with increasing 
concentrations of ponatinib for 2h as indicated. Cells were harvested, lysed, resolved by SDS-PAGE and blotted for: (A) p-ABL-Tyr452, 
c-ABL and β-actin as a loading control; (B) p-SRC-Tyr416 and total SRC, FYN, YES, p-FAK-Tyr576, p-FAK-Tyr577, total FAK, p-Paxillin-
Tyr118, and total paxillin. The β-actin levels were used as loading controls.
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thereby providing FAK with maximal activity [25]. In turn, 
FAK either directly or via SRC, phosphorylates paxillin 
at Tyr118 [26]. We therefore assessed FAK and paxillin 
phosphorylation in merlin-deficient HSC treated for 2h 
with increasing ponatinib concentrations. Western blot 
analysis showed that ponatinib did not reduce FAK-Tyr576 
or Tyr577 or paxillin-Tyr118 phosphorylation similar to 
the SRC-Tyr416 phosphorylation pattern (Figure 2C and 
Supplementary Figure 2). Together the results demonstrate 
that the ABL, SRC, FAK and paxillin pathways are not 
inhibited by ponatinib in merlin-deficient HSC.
Ponatinib decreases activation of the PDGFRα/β, 
PI3K, MEK1/2, ERK1/2 and STAT3 signaling 
pathways
To identify the signaling pathways modulated by 
ponatinib, we conducted a series of Western blots of 
merlin-deficient HSC treated for 2 hours with increasing 
concentrations of ponatinib. We found that ponatinib 
reduced phosphorylation of PDGFRα/β at Tyr849/Tyr857, 
the autophosphorylation sites in the activation loop of these 
kinases, in a dose-dependent manner without altering the 
PDGFRα/β protein levels (Figure 3). In addition, ponatinib 
reduced phosphorylation of three additional tyrosine 
residues in PDGFRβ at positions 740, 771 and 1021 
(Figure 3). Phosphorylation of these residues increases 
affinity for binding and activating PI3K, SRC, the GTPase 
Activator of Ras (GAP), GRB2, and PLCγ [27]. When 
cells are stimulated with growth factors, AKT (also known 
as protein kinase B) and p70 S6 kinase are activated in a 
phosphatidylinositol 3-kinase (PI3K)-dependent pathway. 
Thr308 in the AKT activation loop and Thr229 in the 
p70S6 kinase catalytic domain are phosphorylated by 
3-phosphoinositide-dependent protein kinase-1 (PDK1) in 
vivo and in vitro [28, 29]. Therefore to probe activity of 
the PI3K pathway in ponatinib-treated cells, we assessed 
AKT-Thr308 phosphorylation and p70S6 kinase-Thr229 
Figure 3: Ponatinib inhibited PDGFRα/β phosphorylation in merlin-deficient HSC. Representative ponatinib dose-response 
Western blots (n=3). MD-HSC#45 plated in 12-well plates were treated with increasing concentrations of ponatinib for 2h as indicated. 
Cells were harvested, lysed, resolved by SDS-PAGE and blotted for p-PDGFRα/β-Tyr849/Tyr857, p-PDGFRβ-Tyr740, p-PDGFRβ-Tyr771, 
p-PDGFRβ-Tyr1021 and total PDGFRα and PDGFRβ. The β-actin levels were used as loading controls.
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phosphorylation by Western blots. We found that both 
AKT-Thr308 and p70S6 kinase-Thr229 underwent a dose-
dependent decrease in phosphorylation (Figure 4A,B).
Previous studies demonstrated that overexpression 
and activation of PDGFRβ strongly activates MEK1/2 and 
ERK1/2 in human schwannoma cells leading to enhanced 
proliferation [10]. We assessed the phosphorylated 
MEK1/2 and ERK1/2 levels in merlin-deficient HSC 
after ponatinib treatment. We found that ponatinib 
treatment was associated with a dose-dependent decrease 
in MEK1/2-Ser217/Ser221 and ERK1/2-Thr202/Tyr204 
phosphorylation in merlin-deficient HSC (Figure 4C).
Although net inhibition of SRC phosphorylation 
was not observed, ligand binding to PDGFR promotes 
receptor binding to SRC and recruitment of STAT3, 
followed by Tyr705 auto-phosphorylation of STAT3 and 
its dimerization and translocation into the nucleus to 
directly drive gene expression needed for cell proliferation 
[30-32]. Western blot analysis showed that ponatinib 
decreased STAT3 phosphorylation in a dose-dependent 
manner in merlin-deficient HSC (Figure 4D).
Lastly, to further evaluate the contribution of PI3K/
AKT, MEK, or STAT3 inhibition downstream to PDGFR 
responsible for ponatinib’s effect, we individually 
inhibited AKT with perifosine/KRX-0401, MEK with 
selumetinib/AZD6244, and STAT3 with S3I-201/NSC-
74859 and compared the results to ponatinib’s effects 
on cell viability. MEK, AKT or STAT3 inhibition alone 
only partially decreased merlin-deficient HSC viability. 
Inhibition of STAT3 with S3I-201 was the least effective, 
Figure 4: Downstream signaling pathways inhibited by ponatinib in merlin-deficient HSC. Western blots of extracts 
prepared from merlin-deficient HSC#45 treated with increasing ponatinib concentrations. Quantitation was done by fluorescence intensity 
analysis, normalized to β-actin, and plotted as mean ± SEM (n=3). One-way analysis of variance and Dunnett’s multiple comparison post-
test were used for statistical analysis (* p<0.1; ** p<0.01 and *** p<0.001). Representative Western blots of dose response experiments at 
2h for: (A) p-AKT-Thr308 and AKT; (B) p-p70S6K-Thr229; (C) MEK1/2, p-MEK1/2-Ser217/Ser221, ERK1/2, and p-ERK1/2-Thr202/
Tyr204; (D) p-STAT3-Tyr705, and total STAT3. (E) Ponatinib dose-responseCellTiter-Fluor viability assay. MD- HSC#45 were treated 
with semi-log serial dilutions of ponatinib, NSC-74859, selumetinib, perifosine in 0.1% DMSO for 48h, or vehicle alone. Viability is 
presented as % of the DMSO control. Graph represents the mean ± SEM of three independent experiments.
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and although selumetinib was more efficacious than 
perifosine and S3I-201, none of individual inhibitors 
even at the highest concentration tested (10 μM) matched 
ponatinib’s efficacy (Figure 4E). These results suggest that 
simultaneous inhibition of these three pathways occurs in 
response to ponatinib and similarly contributes to the loss 
of viability of merlin-deficient HSC.
Ponatinib arrests merlin-deficient HSC in G1 by 
decreasing cyclin D1 and increasing p27Kip1 levels
A molecular link between ERK1/2 and STAT3 to 
proliferation is through cyclin D1 to regulate G
1
-to-S 
cell cycle progression. ERK1/2 activity is required for 
expression of cyclin D1 in the G
1
 phase of the cell cycle. 
Moreover, STAT3 transcriptionally regulates cyclin-D1 
by binding to its promoter region [33, 34]. We assessed 
the level of cyclin D1 in merlin-deficient HSC after a 
24h incubation with ponatinib. We found that ponatinib 
strongly decreased cyclin D1 protein levels in a dose-
dependent manner (Figure 5A). These results suggest that 
ponatinib reduces the viability of merlin-deficient HSC 
by inhibiting PDGFRα/β-dependent activation of MEK/
ERK and STAT3 pathways, leading to decreased cyclin 
D1 expression.
To test the possibility that the decrease in the 
viability of merlin-deficient HSC by ponatinib was a 
consequence of cell-cycle blockage due to reduced cyclin 
Figure 5: Ponatinib arrests merlin-deficient HSC at the G1 phase of the cell cycle. (A) Representative Western blots for Cyclin 
D1of lysates prepared from merlin-deficient HSC#45 treated 24h with increasing concentrations of ponatinib. Plotted below as mean ± 
SEM (n=3). One-way analysis of variance and Dunnett’s multiple comparison post-test were used for statistical analysis (** p<0.01 and 
*** p<0.001). (B,C) Merlin-deficient HSC were treated with 3 and 5μM ponatinib for 24h and during the last 3h, 10μM EdU was added. 
Cells were harvested, labeled with live/dead fixable dye, and analyzed by flow cytometry. (B) Representative plots of the distribution of 
EdU- and FxCycle-labelled cells of 0.1% DMSO vehicle control and ponatinib treated cells. (C) Graph of the distribution of the cell cycle 
phases (gated for the live population) of all the experiments as mean ± SEM, n=4; **p<0.01 and ***p<0.001 were determined by two-way 
ANOVA and Bonferroni multiple comparisons post-test. (D) Representative plots of the distribution of live and dead cell population in 
these experiments with increasing concentrations of ponatinib as indicated.
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D1 expression, we analyzed the distribution of cells 
among the different phases of the cell cycle. There was a 
significant increase in the number of cells in the G
1
 phase 
when treated with 3 and 5μM ponatinib compared to 
vehicle controls (72% ±8% and 74% ±7% vs. 47% ±2% of 
control). This was accompanied by a concomitant decrease 
in the number of S-phase cells observed in ponatinib-
treated samples as compared with control samples (7.5% 
±1% for 3μM and 7% ±1% at 5μM vs. 29% ±3% of 
control) (Figure 5B–5C). At the lower concentrations (1 
through 5μM), ponatinib arrested merlin-deficient HSC at 
G
1,
 indicating a cytostatic mechanism of action. However, 
Figure 6: Analysis of G1 regulatory proteins during the cell-cycle in merlin-deficient HSC treated with ponatinib. 
MD-HSC were treated with 3μM ponatinib or vehicle control for 24h. Cells were harvested, fixed, and permeabilized. DNA was stained 
with FxCycle, and intracellular G
1
 regulatory proteins were immunostained and analyzed by flow cytometry. (A) Distribution plots of cells 
with positive/negative p27Kip1 immunostain vs DNA content. Data shown are representative plots of four independent experiments. (B) 
Distribution of cells analyzed by flow cytometry with positive/negative cyclin D1 immunostain vs DNA content. Shown are representatives 
of four independent experiments. (C) Diagram of signaling pathways inhibited by ponatinib in merlin-deficient HSC. Merlin deficiency 
leads to activation of PDGFR, SRC and PI3K. Activation of PI3K potentiates AKT and p70S6K phosphorylation and leads to cell survival, 
growth and G
1
 cell cycle progression. PDGFR activity triggers ERK and STAT3 activation, leading to cyclin D1 expression and cell 
proliferation. SRC activation of FAK and paxillin is not modulated by ponatinib. Ponatinib decreases cell viability through downstream 
inhibition of AKT, ERK, and STAT3.
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by analyzing the live/dead populations, at a higher 
concentration (10μM), ponatinib became cytotoxic (Figure 
5D). The increase in the number of dead cells present in 
the cells treated with 10μM ponatinib coincides with the 
decrease in phosphorylated proteins studied here.
Lastly, we analyzed the correlation of the cell-
cycle phases with levels of several cell cycle regulators. 
Cyclin-dependent kinase (Cdk) inhibitor p27 (p27Kip1) 
is a key negative regulator of Cdk activity in cells 
progressing from G
1
 toward S phase [35]. We analyzed 
the expression of p27Kip1 in conjunction with DNA content 
by flow cytometry. We found fewer p27Kip1-positive cells 
in G
1
 in control cells compared with a large increase in 
p27Kip1-positive cells in G
1
 in ponatinib-treated samples 
(Figure 6A). Similarly, we found a greater number of 
cyclin D1-positive cells in control samples in G
1
 in 
contrast to ponatinib-treated samples (Figure 6B). This 
result correlates with that observed from the Western blot 
experiment (Figure 5A). Overlay of the p27Kip1 and cyclin 
D1 plots with the cell-cycle plots clearly demonstrate that 
ponatinib induced G
1
 arrest with associated changes in 
the cyclin D1 and p27Kip1 levels in merlin-deficient HSC 
(Supplementary Figure 3AB). Our results are consistent 
with ponatinib inhibition of PDGFR and downstream 
PI3K activity leading to a G
1
 cell-cycle arrest of merlin-
deficient HSC by blocking ERK- and STAT3-dependent 
expression of cyclin D1 (Figure 6C).
PDGFRα/β, SRC, STAT 3 and MEK1/2 are 
highly phosphorylated in human vestibular 
schwannomas
To assess activation of PDGFRα/β and SRC in 
human schwannomas, we surveyed a phospho-proteome 
profile comparing five human vestibular schwannoma 
specimens with primary normal adult human Schwann 
cells cultured in the presence of mitogens to stimulate 
their proliferation. Analysis of phospho-receptor tyrosine 
kinase and phospho-kinases proteome profiler arrays 
revealed that schwannomas consistently had higher levels 
of phosphorylated PDGFRα, PDGFRβ, SRC, MEK and 
STAT3 compared with control primary HSC (Figure 7 
A-D). Schwannomas exhibited averaged 6.6 times higher 
PDGFRα phosphorylation, 5.4 times higher PDGFRβ 
phosphorylation, 30 times higher SRC phosphorylation, 
5.6 times higher MEK phosphorylation and 7.4 times 
higher STAT3 phosphorylation compared with control 
primary HSC (Figure 7 A-D).
DISCUSSION
In this study, we evaluated whether ponatinib, 
a BCR-ABL/SRC inhibitor approved for use in 
leukemia, could potentially be repurposed for treatment 
of NF2 schwannomas. Following merlin depletion, 
HSC increased the levels of phosphorylated SRC and 
PDGFRα/β, in agreement with studies in primary human 
NF2 schwannoma cells [36]. Ponatinib stimulated a 
robust G
1
 cell cycle arrest of merlin-deficient HSC in a 
dose-dependent manner by inhibiting PDGFRα/β and its 
downstream effectors AKT, p70S6 kinase, MEK/ERK 
and STAT3, leading to reduced levels of cyclin D1 and 
increased levels of p27Kip1. Intriguingly, ponatinib did not 
reduce ABL/SRC/FAK/paxillin net phosphorylation in 
merlin-deficient HSC. We did not find clear evidence of 
ABL and SRC inhibition in merlin-deficient HSC treated 
with ponatinib. However, we found that ponatinib induced 
a dose-dependent increase in the SRC levels in the HSC. 
Similar results been reported for SRC inhibition with 
AZD0530 of Philadelphia chromosome-positive leukaemia 
cell lines. We speculate that this is due to a compensatory 
feedback mechanism, suggesting SRC kinase inhibition by 
ponatinib [37]. Other SRC family members, such as Fyn 
and Yes, did not change their protein levels in ponatinib-
treated cells. In some CML cases of imatinib resistance, 
upregulation of SRC kinase has been implicated as a 
BCR-ABL-independent mechanism responsible for 
imatinib failure [38-40]. Therefore the increase in SRC 
protein levels observed ponatinib-treated HSC may be an 
adaptive response. It would be interesting to investigate if 
other SRC inhibitors, including SU6656, that have anti-
proliferative activity in primary human schwannoma cells, 
also increase SRC levels [20, 41].
Ponatinib lacked selectivity for the merlin-deficient 
HSC over NF2 wild-type HSC when cultured in the 
presence of serum and mitogens. This is comparable 
to results reported by others with the MEK1 inhibitor 
AZD6244 in primary human schwannoma cells and 
normal Schwann cells grown in serum-containing medium 
[21]. Notably, when cells were incubated in growth 
arresting medium (SCM base + N2 supplement) in the 
presence of 0.25 μM ponatinib for one week, merlin-
deficient HSC showed a greater sensitivity to the drug 
than merlin-expressing HSC. To maintain fetus derived 
cell lines amenable to drug discovery studies, we routinely 
culture these embryonic Schwann cells in the presence of 
serum and other mitogenic supplements, which induces 
Schwann cells to proliferate. In contrast, both myelinating 
and non-myelinating Schwann cells are post-mitotic in 
normal nerves [42-44]. Only after nerve injury do adult 
Schwann cells de-differentiate and proliferate as part of 
the nerve repair process [21, 45-48]. Thus, ponatinib’s 
lack of in vitro selectivity is not a cause for concern for 
in vivo studies and its potential as a therapeutic for NF2-
associated schwannomas.
Ponatinib strongly inhibited PDGFR 
phosphorylation in merlin-deficient HSC. Studies with 
other RTK inhibitors that primarily target PDGFR and 
c-KIT (e.g., nilotinib, imatinib and sorafenib) showed that 
these RTK inhibitors exhibited strong anti-proliferative 
activity on primary human schwannoma and HEI-193 
cells [10, 12, 41]. Merlin was shown to promote the 
Oncotarget31675www.impactjournals.com/oncotarget
internalization of activated PDGFRβ, a role consistent 
with increased expression and activation of mitogenic 
receptors in NF2 schwannomas [13, 14]. In Schwann 
cells, PDGFRα and β signaling are central to cell 
proliferation and survival through the Ras/Raf/MEK/ERK 
and PI3K/AKT signaling pathways [49-51]. In the four 
schwannoma samples with chronic merlin loss, the p-AKT 
Ser473 levels downstream of mTORC2 were reported as 
consistently reduced across tumor samples relative to 
normal arachnoid and meningioma tissues, as well as in 
one immortalized human SC line with acute loss of merlin 
achieved by an RNAi compared to the immortalized 
human merlin-expressing SC line [52]. The consistent 
decrease in mTORC2 signaling activity in schwannoma 
and merlin-deficient Schwann cells mimics the PDGFR 
activity results in schwannomas reported by others and our 
phospho-receptor tyrosine kinase arrays showing a high 
PDGFR phosphorylation levels in all tumors tested (Figure 
7 and 1) [10-12]. Consistent with PDGFR inhibition, we 
observed a dose-dependent decrease in AKT-Thr308 
Figure 7: PDGFRα/β, SRC, MEK and STAT3 are overactive in human schwannomas. (A) Phospho-RTK membrane profile 
of schwannomas and control cultured primary HSC. (B) Bar graph of the quantitation ofp-PDGFRα and p-PDGFRβ membrane dot intensity 
normalized to positive controls. **p<0.005; ****p<0.0001 determined using unpaired t-test of control HSC vs. VS populations, two-tailed. 
(C) Phospho-kinase membrane profile of schwannomas and control cultured primary HSC samples. (D) Bar graph of the quantitation 
of phospho-SRC, phospho-MEK1/2 and phospho-STAT3 membrane intensity normalized to positive controls. *p<0.05; ***p<0.001 
determined using unpaired t-test of control HSC vs. VS populations, two-tailed.
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phosphorylation, a PI3K-dependent phosphorylation site, 
and a decrease in MEK/ERK phosphorylation, similar to 
those reported in sorafenib-treated schwannoma cells [10, 
53, 54]. Moreover, we demonstrated a dose-dependent 
reduction of cyclin D1 levels that correlates with STAT3 
inactivation. STAT3 induces cyclin D1 transcription by 
binding its promoter region; and ERK1/2 has plays a 
critical role for induction of cyclin D1 (Figure 6C) [33, 34, 
55, 56]. Decreased cyclin-D1 expression together with an 
increase in the p27Kip1 level are key to the G
1
 to S phase 
progression block that we observed in ponatinib-treated 
HSCs.
Unlike traditional dual SRC/ABL inhibitors, 
ponatinib is a reversible, third-generation inhibitor 
that binds the unphosphorylated inactive DFG-out 
conformation of both enzymes [57]. Ponatinib was 
designed to overcome resistance-inducing BCR-ABL 
mutations in CML and ALL treated with the first- and 
second-generation TK inhibitors. It is considered a pan-
BCR-ABL inhibitor because it is potently active on ABL-
T315I and fourteen other mutants [19]. Ponatinib shows 
inhibitory activity against ABL/SRC, PDGFR and other 
kinases, including the FGFR (fibroblast growth factor 
receptor), Ephrin receptors, FLT3 (FMS-like tyrosine 
kinase 3), VEGFR1-3 (vascular endothelial growth factor 
receptor 1-3), Ret (rearranged during transfection) and KIT 
(mast/stem cell growth factor receptor) [19]. Ponatinib 
therapy, similar to other TK inhibitors, is associated with 
severe adverse events, such as arterial thrombosis and 
liver toxicity, and older patients (>65 years) had higher 
risk of experiencing adverse effect than younger patients 
[58, 59]. In a large group of children and adolescents 
with CML treated with imatinib, assessment of long term 
growth revealed growth deceleration in both genders 
[60]. Therefore, adverse effects of long-term treatment in 
children should be carefully weighed.
Whereas short-term treatment with ponatinib leads 
to cytostasis, prolonged treatment could lead to cell death 
or senescence [61, 62]. These sequelae have been reported 
for B precursor or T cells from ALL patients treated 
with ponatinib; the treated cells underwent apoptosis 
after a G
1
 cell-cycle arrest by increasing endogenous 
TNF-related apoptosis-inducing ligand (TRAIL) [63]. 
Drugs that simply slow schwannoma growth would 
benefit NF2 patients enormously. If a long-term use of 
ponatinib is envisioned, we speculate that ponatinib may 
be used at lower doses in a combinatorial therapeutic 
approach with other compounds targeting interconnecting 
pathways, thereby limiting adverse effects. The different 
mechanisms of kinase inhibition and diverse range and 
selectivity of small-molecule kinase inhibitors requires 
that each drug be studied in NF2-relevant cell types, and 
weighed independently. To this extent, ponatinib treatment 
effectively reduced viability of merlin-deficient HSC 
with a robust arrest at the G
1
 phase. Ponatinib therapy 
may be applicable to a larger patient population than 
NF2, considering that merlin inactivation also occurs in 
sporadic schwannomas. Future in vivo studies addressing 
ponatinib alone or in combination as an effective therapy 
for schwannomas in NF2 mouse models are warranted.
MATERIALS AND METHODS
Cell cultures and human vestibular 
schwannomas
The merlin-deficient HSC line was generated 
from primary fetal HSC purchased from ScienCell 
(lot #7228) and authenticated by immunostaining for 
expression of human nuclear antigen, and SC markers, 
S100, PLP, O4, and Gap43, and Nestin. Cells were 
transduced with lentiviral particles expressing human 
NF2 gene-specific shRNA (GenBank accession no. 
NM_000268; TRCN0000237845; TRCN0000039974; 
TRCN0000039975 and TRCN0000039977, Sigma-
Aldrich), shRNA Scrambled, or Turbo-GFP control 
(Sigma-Aldrich) and then selected with 0.5 mg/ml 
puromycin. Wild-type and merlin-deficient HSC were 
cultured in CellBIND dishes (Corning) in complete 
Schwann cell media (SCM) from ScienCell (basal 
Schwann cell medium plus 5% fetal bovine serum, 
Schwann cell growth supplements which contains growth 
factors, hormones, and proteins necessary for the culture 
of normal human Schwann cells and 1X-penicillin/
streptomycin) unless otherwise specified. Cells were used 
between passages 9 to 18. Merlin levels were assessed by 
Western blotting.
Frozen human schwannomas used in phospho-
proteome studies were procured with patient informed 
consent at The Ohio State University College of Medicine 
according to Institutional Review Board regulations. 
Human vestibular schwannoma (VS) cells cultured to test 
ponatinib efficacy were isolated from dissociated fresh 
human tumors. Fresh VS specimens were procured with 
patient informed consent at University of Miami Miller 
School of Medicine according to Institutional Review 
Board regulations through the Tissue Bank Core Facility.
Normal primary human SCs, a gift from Dr. Patrick 
Wood (The Miami Project to Cure Paralysis, University of 
Miami Miller School of Medicine), were used in phospho-
proteome studies, and cultured as previously described [64].
Antibody proteome profiler arrays
Human phospho-RTK (ARY001) and phospho-
kinase array (ARY003) kits were purchased from R&D 
systems. Human schwannoma homogenates and control 
HSC lysates were prepared and analyzed according to 
manufacturer’s instructions. Arrays were visualized with 
chemiluminescence and were quantified with ImageJ 
MicroArray_Profile.jar plugin or Carestream software; 
mean intensity of duplicate spots was calculated.
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Antibodies and inhibitors
Rabbit antibodies against merlin (D1D8), c-ABL, 
phospho-AKT (Thr308; C31E5E), cyclin-D1 (92G2), 
FYN, p-MEK1/2 (Ser217/221), PDGFRα and β, SRC 
(36D10), p-SRC family (Tyr416), p-ERK1/2 (D13.14.4E), 
YES and mouse antibodies recognizing AKT (40D4), 
β-Actin (8H10D10), MEK1/2 (L38C12), ERK1/2, p27Kip1 
(SX53G8.5) were purchased from Cell Signaling. Rabbit 
antibodies against p-paxillin (Tyr118) and p-FAK (Tyr577/
Tyr576) were purchased from Invitrogen. Rabbit p70 
S6 kinase (Thr229) was purchased form ThermoFisher 
Scientific. Rabbit anti-p-ABL (Tyr245), and human 
nuclear antigen antibodies were obtained from Millipore 
and antibodies for myelin- proteolipid protein and GAP43 
were from Abcam. The anti-S100 antibody was purchased 
from Dako. Mouse anti-paxillin antibody was from BD 
bioscience. Secondary antibodies, goat anti-rabbit IgG 
conjugated with DyLight 800 4X-PEG, goat anti-Mouse 
IgG conjugated with DyLight 680, were purchased from 
Cell Signaling. Ponatinib, perifosine/KRX-0401, and 
selumetinib/AZD6244 were purchased from SelleckChem. 
The STAT3 inhibitor S3I-201/NSC-74859 was purchased 
from MedChem Express.
Western blot analysis
Cultured HSCs were lysed in modified RIPA buffer 
as previously described [65] or in 1X-SDS loading 
buffer plus 2.5 U/ml benzonase. 10 μg of protein or 10 
μl 1X-loading buffer lysate were resolved in 4–20% 
polyacrylamide gels (Pierce), transferred to PVDF 
membranes (Immobilon-FL; Millipore), blocked with 
5% BSA in TBS, and incubated with primary antibodies 
overnight at 4°C, and then with their corresponding 
fluorescence-conjugated secondary antibodies at 1:25,000-
1:40,000 dilution. Image acquisition was done using LI-
COR® Biosciences Odyssey® Infrared Imaging System 
and quantification using Odyssey Image Studio Version 
3.1software and ImageJ 1.46r.
Immunocytochemistry
Cells were grown on German glass coverslips coated 
with 200 μg/ml poly-L-lysine (Sigma-Aldrich). HSCs 
were fixed in 4% paraformaldehyde and immunostained, 
and stained images were acquired with a Zeiss LSM710 
confocal microscope as previously described [64]. Images 
were processed with ZEN2011 software.
Cell viability assay
HSC were seeded at 2,500 cells/well in 20 μl of 
phenol-red free SCM (SCM phenol-red free base, 5% 
serum, Schwann cell growth supplements containing 
growth factors, hormones, and proteins and 1X-penicillin/
streptomycin) in 384-well plates and incubated with 
increasing concentrations of ponatinib in 0.1% DMSO or 
vehicle alone for 48h. The CellTiter-Fluor cell viability 
assay (Promega) was used according to manufacturer’s 
specifications [53].
To evaluate cell viability without artificially 
stimulating proliferation, control and merlin-deficient HSC 
were cultured and assayed in growth suppressive medium 
(SCM base, 1X-penicillin/streptomycin –ScienCell, plus 
N2 supplement-Invitrogen). Cells were seeded in 24 well 
plates (Corning-CellBIND) at 60,000 cells/well in four 
replicates, after 4 days incubation at 37°C, 7% CO
2
, cells 
were treated with 0.25μM ponatinib or a vehicle control 
for one week. Viability was assessed with a crystal violet 
assay as previously described [64].
To evaluate cell viability of primary VS cells with 
NF2 mutations, two fresh VS were obtained from the 
Tissue Bank Core Facility at the University of Miami 
Miller School of Medicine. VS tumors were cut into 1 
mm pieces and dissociated in 0.5 mg/ml collagenase 
(~150U/ml) and dispase (2.5 mg/ml) in Dulbecco’s 
Modified Eagle Medium (Sigma) for 1h followed by 
0.25% Trypsin for 30 minutes at 37°C. Digested tissue 
was triturated and centrifuged at 1500 rpm at 4°C 
for 10 minutes. Supernatant was discarded and cells 
were resuspended and cultured using Schwann Cell 
Media (ScienCell) on culture flasks pre-treated with 
0.1% poly-L-lysine (Sigma) and 25 mg/ml laminin 
(ThermoScientific). Cells from Passage 2 were then 
seeded in a 96 well plate (Costar, Corning) at 5,000 
cells/well in six replicates. After 24 hours of incubation 
at 37°C, 5% CO2, cells were treated with ponatinib 
at different concentrations or 0.05% DMSO for 48h. 
Viability was assessed with a crystal violet assay as 
previously described [64].
DNA sequencing of VS
Genomic DNA was isolated and purified using 
Trizol (Invitrogen) as per the manufacturer’s protocol. 
A total of 17 pairs of primers were designed for the 
amplification and sequencing of the coding exons and 
their flanking splice sites using the Primer 3 program 
(http://bioinfo.ut.ee/primer3-0.4.0/). The complete coding 
sequences of NF2 were amplified by PCR. DNA (~1 μg) 
was amplified with NF2-specific primer pairs in 50μL, 
containing 10X PCR Buffer (pH 8.5), 0.4 mM dNTP mix 
(Promega Corporation), 0.4 pmol/μL of each primer, 
and 0.0625 units of Taq DNA polymerase (Eppendorf 
AG). DNA templates were amplified using the following 
program: 95°C for 3 min; 35 cycles of 94°C for 50 s, 60°C 
for 50 s, 72°C for 60 s; and final extension of 72°C for 
5 min. Direct sequencing of PCR products were performed 
on both strands using the ABI Prism BigDye Terminator 
reaction kit and ABI 3100 DNA sequencer or with 
Beckman Coulter 2000 XL instrument and appropriate 
kits.
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Cell-cycle and G1 proteins analysis by flow 
cytometry
The Click-iT EdU, FxCycle stain and Live/
Dead fixable dead cell stain kits were purchased from 
Molecular Probes (ThermoFisher Scientific). Cells 
were seeded in 6-well plates and treated overnight with 
an inhibitor or vehicle. On the next day, 10 μM EdU 
was added to the cultures for 3 h, and then cells were 
harvested (total 24-h inhibitor incubation), stained 
with fixable violet live/dead stain, and permeabilized. 
EdU and DNA labeling was conducted according to 
manufacturer’s instruction. Cell cycle analysis was done 
on gated live cells. For the cyclin D1/p27Kip1 expression 
study [66], cultures were treated with an inhibitor 
or vehicle for 24 h and then harvested, fixed with 4% 
paraformaldehyde for 10 min at 37°C, chilled for 1 min, 
and permeabilized for 30 min in 90% methanol. Fixed 
cells were transferred to a Falcon 5 ml tube through a cell 
strainer cap, rinsed twice with 0.5% BSA in PBS, and 
immunostained by incubating for 1h at room temperature 
with a cyclin D1 (1:400) or p27Kip1 (1:3,000) antibody, 
followed by a 30-min incubation with a goat anti-rabbit 
or anti-mouse-Alexa488 secondary antibody. After one 
wash, cells were resuspended in 1 ml of 0.5% BSA and 
stained for 30 min with 200nM FxCycle Far Red DNA 
stain supplemented with 0.1mg/ml of ribonucleaseA 
(Invitrogen). A BD FACS Canto-II flow cytometer (BD 
Biosciences) with the BD FACSDiva™ 6.1.3 software 
was used for data acquisition and FlowJo software was 
used for data analysis.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism v5.0 for Windows. Ponatinib dose-response 
experiments were analyzed by non-linear regression 
(four parameters). Other experiments were analyzed 
by applying two-way ANOVA and Bonferroni multiple 
comparisons post-test, one-way ANOVA, and Dunnett’s 
multiple comparison post-test or unpaired t-test, two-tailed 
as noted.
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